In February 2026, NeoGenomics, Inc. announced PanTracer Pro, a new test that combines comprehensive genomic profiling, ...

NeoGenomics, Inc. NEO recently announced the availability of its new pan-solid tumor assay, PanTracer Pro, designed to help ...

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on NeoGenomics. NeoGenomics has received a total of ratings ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday before the bell. Here’s what investors should know. NeoGenomics beat analysts’ revenue ...

Analysts expect earnings of 4 cents a share on revenue of $188.1 million, representing modest sequential improvement from the third quarter, when the company posted earnings of 3 cents per share on ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth ...

NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for NeoGenomics. The company has an ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

Management raised full-year 2025 revenue guidance to $747 million-$759 million, reflecting 13%-15% growth. Adjusted EBITDA guidance remains unchanged at $55 million-$58 million. Pathline is projected ...

CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, marking nine consecutive quarters of double-digit growth. He also announced his retirement effective ...

NeoGenomics (NEO), a Fort Myers-based cancer testing and research lab, surprised Wall Street Monday with higher-than-expected third-quarter revenue and break-even earnings per share. The company ...